Cellectis S.A. (CLLS)
NASDAQ: CLLS · Real-Time Price · USD
1.640
+0.050 (3.14%)
Dec 20, 2024, 4:00 PM EST - Market closed
Cellectis Revenue
Cellectis had revenue of $18.05M in the quarter ending September 30, 2024, with 997.99% growth. This brings the company's revenue in the last twelve months to $36.04M, up 46.96% year-over-year. In the year 2023, Cellectis had annual revenue of $9.19M, down -64.26%.
Revenue (ttm)
$36.04M
Revenue Growth
+46.96%
P/S Ratio
n/a
Revenue / Employee
$163,086
Employees
221
Market Cap
155.56M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 9.19M | -16.53M | -64.26% |
| Dec 31, 2022 | 25.72M | -12.87M | -33.35% |
| Dec 31, 2021 | 38.60M | -20.97M | -35.20% |
| Dec 31, 2020 | 59.56M | 36.57M | 159.09% |
| Dec 31, 2019 | 22.99M | 1.56M | 7.27% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Adaptimmune Therapeutics | 175.04M |
| Sutro Biopharma | 160.96M |
| Seres Therapeutics | 126.33M |
| The Joint | 120.80M |
| Pro-Dex | 56.80M |
| Nanobiotix | 45.22M |
CLLS News
- 9 days ago - Cellectis: Poised To Start Answering Questions In 2025 - Seeking Alpha
- 11 days ago - Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB) - GlobeNewsWire
- 6 weeks ago - Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting - GlobeNewsWire
- 6 weeks ago - Cellectis S.A. (CLLS) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Cellectis Provides Business Updates and Financial Results for Third Quarter 2024 - GlobeNewsWire
- 7 weeks ago - Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024 - GlobeNewsWire
- 2 months ago - Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress - GlobeNewsWire
- 3 months ago - Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety - GlobeNewsWire